Spero Therapeutics LLC
Enfeebling Pseudomonas with a chemical inhibitor of transcription
Spero Therapeutics LLC was formed to develop antibiotics based on a novel mechanism, to treat infections with high unmet need. Its lead program, initiated in 2013, commercializes the research of Laurence Rahme of Mass General, who invented a method for using small molecules to inhibit MvfR, a transcription regulator utilized by gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella.